key: cord-0066706-kc5zizqa
authors: Hsieh, Ming-Shun; Hu, Sung-Yuan; Liao, Shu-Hui; Chang, Chia-Ming; Hsieh, Vivian Chia-Rong; How, Chorng-Kuang
title: Type 2 Diabetic Sepsis Patients Have a Lower Mortality Rate in Pioglitazone Use: A Nationwide 15-Year Propensity Score Matching Observational Study in Taiwan
date: 2021-07-23
journal: Emerg Med Int
DOI: 10.1155/2021/4916777
sha: 08f4f6da7597e1f3b317b4baa653ac011122d7d9
doc_id: 66706
cord_uid: kc5zizqa

BACKGROUND: Pioglitazone use via the PPARγ agonist in sepsis patients is inconclusive. It was based on a great number of animal studies. However, except for information from animal studies, there are merely any data of human studies for reference. METHODS: This study was conducted by a unique database including 1.6 million diabetic patients. From 1999 to 2013, a total of 145,327 type 2 diabetic patients, first admitted for sepsis, were enrolled. Propensity score matching was conducted in a 1 : 5 ratio between pioglitazone users and nonusers. Multivariate logistic regression was conducted to evaluate the adjusted odds ratios (aORs) of hospital mortality in pioglitazone users. Further stratification analysis was done and Kaplan–Meier plot was used. RESULTS: A total of 9,310 sepsis pioglitazone users (defined as “ever” use of pioglitazone in any dose within 3 months prior to the first admission for sepsis) and 46,550 matched nonusers were retrieved, respectively. In the multivariate logistic regression model, the cohort of pioglitazone users (9,310) had a decreased aOR of 0.95 (95% CI, 0.89–1.02) of sepsis mortality. Further stratification analysis demonstrated that “chronic pioglitazone users” (defined as “at least” 4-week drug use within 3 months) (3,399) were more associated with significant aOR of 0.80 (95% CI, 0.72–0.89) in reducing sepsis mortality. CONCLUSIONS: This first human cohort study demonstrated the potential protective effect of chronic pioglitazone use in type 2 diabetic sepsis patients.

Sepsis is a major cause of mortality worldwide, especially in the immunocompromised patients, such as those with multiple comorbidities [1] [2] [3] . Sepsis is a complex syndrome that is induced by severe infection with a series of unregulated immune responses, caused majorly by the proinflammatory cytokines. Acute organ failure and subsequent high mortality rate will induce long-term morbidities, such as stroke and cardiovascular diseases [3, 4] . Despite advances in treatment strategies, therapies to mitigate the severity of sepsis are currently unsatisfactory [5] .

iazolidinediones (TZD), a kind of oral antidiabetic drugs (OADs), are used for the treatment of type 2 diabetes via being the insulin sensitizers [6] . Currently, pioglitazone is the only TZD available in the market. It is proposed to have a protection effect during the sepsis course by acting as the peroxisome proliferator-activated receptor-gamma (PPARc) agonist [7] . Because of multiple concerns about TZDs' complications, for example, cardiovascular disease and urinary bladder cancer, the prescriptions of TZD decreased significantly, from 9.20% in 2006 to 2.86% in 2012 in Taiwan [8] [9] [10] .

Accumulating evidence in animal studies demonstrated that PPARc agonists improved the outcomes of sepsis via multiple mechanisms [11] . In the mouse model, pioglitazone administration decreased inflammation and improved survival of sepsis induced by cecal ligation and puncture (CLP) [12] . Because of the growing amount of evidence, the randomized clinical trial of pioglitazone use in sepsis patients is underway [13] . However, currently, there are limited data on this topic in humans, especially in type 2 diabetic patients, because the varied levels of diabetic complication burdens in each person were not easily compared [14] .

In the current study, we used a specially applied nationwide database of diabetic patients, from 1999 to 2013, with the first admission for sepsis to evaluate the impacts of pioglitazone use in sepsis with the main outcome of the total hospital mortality.

is cohort study addressed the selection bias from diabetic severity by using the propensity score matching and simulated a real-world clinical trial to compare subjects in each group.

We conducted this cohort study by using the National Health Insurance Research Database (NHIRD) of Taiwan. e National Health Insurance program in Taiwan currently provides coverage for more than 99% of the entire population. e National Health Insurance in Taiwan provides excellent healthcare service to the people [15] [16] [17] [18] . e deidentified patient information and claims data were released to the National Health Research Institute to establish the NHIRD. e diagnosis codes of the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) are used.

From the NHIRD, we conducted this study by using the specially applied database of "Longitudinal Cohort of Diabetes Patients (LHDB)" which enrolled a longitudinal cohort of 1.6 million newly diagnosed diabetic patients from 1999 to 2013. We retrieved data from LHDB to constitute the study and comparison cohorts, composed by type 2 diabetic patients with a first admission for sepsis with and without pioglitazone use.

e diagnosis of sepsis in the current study was retrieved using the ICD-9-CM code 038 plus a main infection diagnosis with antibiotics prescription. e accuracy of sepsis diagnosis in the NHIRD has been validated [19] . e patients were defined as having certain comorbidities if they had at least 2 outpatient service claims or if they had a single hospitalization in which the certain comorbidities were found. e index date was defined as the first admission date for sepsis. In this study, if a  patient received the prescription of any dose of pioglitazone  within 3 months prior to the index admission for sepsis, he  or she would be defined as a pioglitazone user or "ever use"  pioglitazone. roughout the whole study, we used the above definition to describe any drug use.

To reduce the medical expenditure for the stable patients of type 2 diabetes or other chronic diseases, the physicians can use the refill card of consecutive prescription for 3 months rather than prescribing the drugs week by week or only 3 days. Based on the above medical regulation and culture in Taiwan, we therefore defined a person as a "chronic" pioglitazone user if he or she was prescribed pioglitazone for at least 4 weeks within 3 months prior to the first admission for sepsis [20] .

Matching. Propensity score matching could reduce the selection bias because it allowed the bundling of many confounding factors which were frequently presented in the observation studies [21] [22] [23] . We calculated the propensity score using the multivariate logistic regression by entering the baseline covariates which included age, sex, comorbidities, insurance premium, and complication severity of type 2 DM.

Since type 2 diabetes related complications may be the most important factor to determine the hospital outcome, we matched 1 study cohort patient with 5 comparison cohort patients according to propensity score and obtained a dataset composed of matched patients who had a statistically identical likelihood of severity of diabetic complications.

In the database, the individual insurance premium fee paid was a useful surrogate for the household income level [24] .

e algorithm used for participant selection for the study and comparison cohorts is shown in Figure 1 . Patients aged <18 or >100 years, patients with type 1 diabetes, and patients infected with human immunodeficiency virus were excluded from this study. Since the database contains deidentified data for research, our study was exempted from the requirement of informed consent from participants. is study was approved by the Institutional Review Board of Taipei Veterans General Hospital (2020-01-012CC) and China Medical University (CMUH104-REC2-115).

Differences in demographic characteristics, insurance premium, baseline comorbidities, medications (including nonsteroidal anti-inflammatory drugs (NSAIDs), aspirin, statins, biguanides, dipeptidyl peptidase-4 inhibitors (DPP-4 inhibitors), sulfonylureas, pioglitazone, insulin, immunosuppressants, and steroids), infection sites, adapted diabetes complications severity index (aDCSI) score which was a representation of diabetes complication severity, length of hospital stay, and the total hospital mortality were examined using the chi-squared test and two-sample t-test.

Odds ratios (ORs) and 95% confidence intervals (95% CIs) were calculated for each variable in the logistic regression model. Adjusted ORs (aORs) for the total hospital mortality were obtained after adjusting for potential confounders, including age, sex, income, and comorbidities, in the multivariate logistic regression analysis. Kaplan-Meier analysis with logrank test was conducted to compare the difference in the outcomes of total hospital mortality between the study and comparison cohorts (i.e., pioglitazone users versus nonusers). e statistical analyses were performed using the SAS 9.4 statistical package (SAS Institute, Inc., Cary, NC, USA). A P value of 0.05 was considered significant.

Nonusers. From the LHDB, we initially retrieved a total of 145,327 type 2 diabetic patients with the first admission for sepsis from 1999 to 2013. After propensity score matching, a total of 9,310 pioglitazone users and 46,550 nonusers were included for further analysis.

Before PS matching, the mean ages of pioglitazone users and nonusers were 67.08 ± 12.62 and 71.13 ± 13.90 years, respectively. After PS matching, the mean ages of pioglitazone users and nonusers were 68.11 ± 12.50 and 68.96 ± 13.18 years, respectively. e detailed demographic characteristics are shown in Table 1 . Before matching, a greater proportion of pioglitazone users than nonusers received treatment with statins (30.85% versus 11.52%), biguanide (60.48% versus 28.80%), DPP-4 inhibitors (21.35% versus 3.52%), sulfonylurea (65.17% versus 31.84%), and insulin (68.11% versus 43.37%) (all P < 0.001). e pioglitazone users had fewer respiratory system infection sites compared to nonusers (46.24% versus 51.76%) (P < 0.001). e pioglitazone users had more severe complication burdens (aDCSI score ≥ 5, 16.30% of pioglitazone users versus 8.95% of nonusers) (P < 0.001). However, the pioglitazone users had lower total hospital mortality rate (15.83% versus 18.6%) and shorter length of hospital stay (mean, 11 versus 12 days) than the nonusers.

In the logistic regression model, after further adjusting for age, sex, income, and comorbidities, the pioglitazone users (ever use) were shown to have a nonsignificant aOR slightly less than unity for total hospital mortality (aOR � 0.95 (95% CI, 0.89-1.03)) ( Table 2 ).

In the further stratification analysis, the patients who were classified as "chronic pioglitazone users" demonstrated the significant aOR for total hospital mortality (aOR � 0.80 (95% CI, 0.72-0.89), P < 0.05) ( Table 3) .

In the Kaplan-Meier analysis with log-rank test, the total hospital mortality did not differ significantly between the pioglitazone users ("ever use") and nonusers ( Figure 2 ). However, in the "chronic pioglitazone users," it was obvious 4 Emergency Medicine International that the cumulative survival rate was much better than that in the nonusers (P < 0.01) (Figure 3 ).

In this real-world study, by using the nationwide database of diabetic patients with propensity score matching, we demonstrated that pioglitazone use can exert a significantly protective effect in "chronic pioglitazone users." is finding has been proved in multiple animal studies for a long term. However, it remained controversial in human beings. To the best of our knowledge, this is the first and largest cohort study of type 2 diabetic sepsis patients that simulated the human clinical trial via propensity score matching to examine the protective effect of pioglitazone. Our finding will surely attract more and more attention focusing on the potential of pioglitazone in sepsis. PPARs encoded by separate genes, PPARα, PPARβ⁄ δ, and PPARc, are expressed by a variety of cells of the immune system including macrophages, B and T, and monocytes, lymphocyte, natural killer cells, dendritic cells, mass cells, neutrophils, and eosinophils [25] . PPARs have received attention till now, since they play pivotal regulators in adipocyte differentiation, glucose homeostasis, and immune regulation. In the current study, we focus on the role of immune modification of pioglitazone which is a kind of TZDs, activating as the PPARc agonist.

PPARc agonists can be simply classified into natural and artificial ones, respectively. Natural PPARc agonists include saturated and unsaturated fatty acids, eicosanoid derivatives, such as 15-deoxy-Δ 12,14 -prostaglandin J2 (15d-PGJ2), and oleic and nitrated linoleic acids. Synthetic PPARc agonists are represented by TZDs, such as pioglitazone, rosiglitazone, troglitazone, and ciglitazone. TZDs (agonist) function via activating the PPARc receptor [26, 27] . In the absence of PPARc agonists, these ligands remain inactive via binding to the corepressors.

Pioglitazone is currently the only available TZD in the market, since rosiglitazone has been suspended in Taiwan in 2011 due to its potentially increased risk of myocardial infarction and decompensated heart failure [28] . Pioglitazone targets the transcription of PPARc and is involved in Adjusted OR: adjusted for age, sex, insurance premium, and comorbidities in logistic regression. Any dose of pioglitazone within 3 months prior to the index admission for sepsis; * P < 0.05. CI, confidence interval; CKD, chronic kidney disease; CLD, chronic liver disease; COPD, chronic obstructive pulmonary disease; DPP-4 inhibitor, dipeptidyl peptidase-4 inhibitor; HTN, hypertension; IHD, ischemic heart disease; NSAID, nonsteroidal anti-inflammatory drug; NT, new Taiwan; OR, odds ratio; PAOD, peripheral arterial occlusion disease. Emergency Medicine International 5 metabolic homeostasis, and, most important of all, it much improves insulin sensitivity. is mechanism provides a choice to type 2 diabetic patients before receiving insulin injection therapy. Following the suspension of rosiglitazone in 2011, pioglitazone later became another target of criticism, including that pioglitazone (1) increased the risk of Emergency Medicine International osteoporosis and (2) increased the risk of urinary bladder cancer. However, supporting data to pioglitazone passed these [29, 30] . Moreover, many studies and specialist opinion support that pioglitazone should continue to be used in T2D treatment [31] [32] [33] .

In addition to helping glucose control, the activation of PPARc agonist of pioglitazone contributes to the modulation of inflammation [34] . Pioglitazone improving bacterial elimination in the peripheral blood, via inhibition of proinflammatory molecules such as IL-6, TNF, IL-1, and IL-12, has been well documented. It also enhanced bacterial elimination in the liver by increasing the phagocytic and bactericidal activities [11] . Furthermore, accumulated evidence of animal models demonstrated that pioglitazone is effective in the prevention and treatment of sepsis in mice cecal ligation and puncture (CLP) model [35] [36] [37] . In the type 2 diabetic patients, who are prone to infection diseases, TZDs use with pioglitazone should be an adequate choice via the anti-inflammatory and enhancing bactericidal effects. Our study demonstrated the protective effect in sepsis patients, which added a new important evidence in human body.

e repeated or accumulated doses of pioglitazone presented the dose-effect relationship compared with the single-dose use as observed in this study. Besides, PPARc agonists are known to upregulate their receptors' expression, which render the greater anticipated effects of repeated or accumulating dosing [38] . However, currently, which is the optimal dose and which stage to start pioglitazone treatment in sepsis deserve further investigation. Combining with other studies, we inferred that the initial or chronic use of pioglitazone might inhibit the cytokine storm and therefore reduced the acute organ failure in the first fulminant stage. Continuous use during the sepsis course remains for further study.

is study has several limitations. First, this study lacked certain important laboratory data, that is, initial blood glucose level and hemoglobin A1C (HbA1c), which was an inevitable weak point in administrative database studies. However, we had demonstrated that there was no association between initial blood glucose, HbA1c, and hospital outcomes of sepsis in our previous hospital-based study; the lack of initial blood glucose level and HbA1c may be not as important as previously thought [14] . Second, the impact of pioglitazone use on every sepsis stage remains further examined since systemic inflammatory response syndrome (SIRS) and subsequent compensatory anti-inflammatory response syndrome (CARS) might occur in sequence or concurrently, named as mixed antagonist response syndrome (MARS). Our study design mainly focused on the first stage, that is, SIRS.

In this study, we demonstrated that, currently, regular preadmission pioglitazone use improved the total hospital mortality in type 2 diabetic sepsis patients after considering multiple variables, including comorbidities and household income.

Data Availability e data that support the findings of this study were taken from the LHDB, but restrictions apply to the availability of these data, which were used under license for the current study. So the data are not publicly available. e data are however available from the authors upon reasonable request.

Highlights. (1) is nationwide database in Taiwan which included 1.6 million diabetic patients from 1999 to 2013 was used to examine the potential protective effect of pioglitazone in type 2 diabetic sepsis patients. (2) Propensity score matching to avoid selection bias and aDCSI score (representation of DM severity) to evaluate diabetes severity were addressed to retrieve the pioglitazone users (9,310) and nonusers (46,550) as the study and comparison cohort. (3) To the best of our knowledge, this is the first and largest cohort study to examine the potentially protective effects from pioglitazone use in sepsis, which was limited to animal studies. (4) In the stratification analysis, the study results demonstrated that pioglitazone use (at least 7 days within 3 months) was significantly associated with decreased mortality in sepsis patients.

is study was conducted by using the Longitudinal Cohort of Diabetes Patients (LHDB) in Taiwan. e LHDB contains deidentified secondary data for research.

is study was approved by the Institutional Review Board of Taipei Veterans General Hospital (2020-01-012CC) and China Medical University (CMUH104-REC2-115).

e authors declare that there are no conflicts of interest.

Assessment of the worldwide burden of critical illness: the intensive care over nations (ICON) audit

Assessment of global incidence and mortality of hospital-treated sepsis. current estimates and limitations

e third international consensus definitions for sepsis and septic shock (sepsis-3)

Long-term mortality and major adverse cardiovascular events in sepsis survivors. a nationwide population-based study

Septic shock-evaluating another failed treatment

Pioglitazone ameliorates insulin resistance and diabetes by both adiponectin-dependent and -independent pathways

PPAR gamma: from definition to molecular targets and therapy of lung diseases

Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes

e use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study

e prescribing trend of oral antidiabetic agents for type 2 diabetes in Taiwan

Pioglitazone improves phagocytic activity of liver recruited macrophages in elderly mice possibly by promoting glucose catabolism

Pioglitazone reduces systematic inflammation and improves mortality in apolipoprotein E knockout mice with sepsis

Phase 1 safety and pharmacokinetic study on the use of pioglitazone in critically ill patients with sepsis: a randomized clinical trial

Hospital outcomes and cumulative burden from complications in type 2 diabetic sepsis patients: a cohort study using administrative and hospital-based databases

Cloud image data center for healthcare network in Taiwan

Protecting health care workers during the COVID-19 coronavirus outbreak -lessons from Taiwan's SARS response

Initial rapid and proactive response for the COVID-19 outbreak -Taiwan's experience

Policy decisions and use of information technology to fight 2019 novel coronavirus disease, Taiwan

Association of postdischarge rehabilitation with mortality in intensive care unit survivors of sepsis

Association between nucleoside analogues and risk of hepatitis B virus-related hepatocellular carcinoma recurrence following liver resection

An introduction to propensity score methods for reducing the effects of confounding in observational studies

Estimating effects of nursing intervention via propensity score analysis

Assessing balance in measured baseline covariates when using many-to-one matching on the propensity-score

Preadmission antihypertensive drug use and sepsis outcome: impact of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs)

An overview on biological mechanisms of PPARs

PPAR(c) and glucose homeostasis

Molecular recognition of nitrated fatty acids by PPARc

FDA warning and removal of rosiglitazone from VA national formulary

Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study

Pioglitazone and bladder cancer: a populationbased study of Taiwanese

Pioglitazone: the forgotten, cost-effective cardioprotective drug for type 2 diabetes

Pioglitazone has a dubious bladder cancer risk but an undoubted cardiovascular benefit

Pioglitazone use and risk of bladder cancer in patients with type 2 diabetes: retrospective cohort study using datasets from four European countries

Peroxisome proliferator-activated receptor-gamma is a new therapeutic target in sepsis and inflammation

Pioglitazone reduces inflammation through inhibition of NF-κB in polymicrobial sepsis

Effects of pioglitazone on survival and omental adipocyte function in mice with sepsis induced by cecal ligation and puncture

Novel therapeutic agents in pediatric sepsis: peroxisome proliferator receptor c (PPAR c) agonists

Down-regulated peroxisome proliferator-activated receptor c (PPARc) in lung epithelial cells promotes a PPARc agonist-reversible proinflammatory phenotype in chronic obstructive pulmonary disease (COPD)

Development Center of Taichung Veterans General Hospital, Taichung, Taiwan, for their assistance in data retrieval from the electronic database and further classification.

Supplementary 

Ming-Shun Hsie, Sung-Yuan Hu, and Chia-Ming Chang contributed to the conception and design. Vivian Chia-Rong Hsieh and Shu-Hui Liao performed data analysis and interpretation. Ming-Shun Hsieh wrote the manuscript. Chorng-Kuang How gave the final approval and performed critical revision. All the authors read and approved the final manuscript. Vivian Chia-Rong Hsieh and Chorng-Kuang How contributed equally to this study.